Real Hope For Lupus As AZ's Anifrolumab Impresses In Phase II
This article was originally published in Scrip
Executive Summary
A Phase II trial of AstraZeneca's investigational monoclonal antibody, anifrolumab, in patients with moderate-to-severe systemic lupus erythematosus (SLE) met its primary and secondary endpoints. The data were presented at the American College of Rheumatology 2015 Scientific Meeting in San Francisco this week.
You may also be interested in...
New Life For AstraZeneca’s SLE Treatment As Second Study Succeeds
The second Phase III TULIP trial for AstraZeneca’s anifrolumab has succeeded where the first failed by hitting a new primary endpoint in systemic lupus erythematosus.
TULIP Fever: AstraZeneca Catches Cold With Disappointing Lupus Data
Another one of AstraZeneca’s more left-field product candidates, its investigational lupus therapy anifrolumab, has disappointed at Phase III.
Deal Watch: Array Partners With Ono On Cancer Drugs In Japan, South Korea
French biotechs Servier and ILTOO sign an option agreement for the latter's IL-2 inhibitor for lupus, while Korean biotechs LegoChem and Bridge will team up in idiopathic pulmonary fibrosis.